The European Medicines Agency (EMEA) approved efalizumab (Raptiva) for the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to, other systemic therapies including cyclosporine, methotrexate and PUVA.
The Food and Drug Administration (FDA) approved efalizumab for the treatment of adult patients (>18 years old) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Efalizumab was tested in a phase II study to treat psoriasis arthritis. However, there was no significant clinical improvement detected in treated patients in comparison with the placebo group.
Case reports were published about the use of efalizumab in patients with dermatomyositis, palmo-plantar pustulosis or atopic dermatitis.
Was this article helpful?